Drugs & Aging

, Volume 24, Issue 5, pp 429–440 | Cite as

Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with Statins

  • Sabin S. Egger
  • Alexandra E. Rätz Bravo
  • Lorenzo Hess
  • Raymond G. Schlienger
  • Stephan Krähenbühl
Original Research Article


Background and objective

Elderly patients may be at higher risk of drug-drug interactions (DDIs) because of polypharmacy. This study evaluated age-specific differences in the prevalence of clinically relevant potential DDIs (pDDIs) in ambulatory dyslipidaemic patients treated with an HMG-CoA reductase inhibitor (statin). We hypothesised that elderly patients are at higher risk for pDDIs because of the presence of more drugs and drugs with a higher potential for DDIs in this age group.


A total of 2742 dyslipidaemic ambulatory patients treated with a statin were included in this cross-sectional study. Drug treatment was screened for clinically relevant pDDIs using an electronic drug interaction program (DRUG-REAX® System).


The study sample consisted of 483 (17.6%) patients aged ≤54 years, 732 (26.7%) aged 55–64 years, 924 (33.7%) aged 65–74 years and 603 (22.0%) patients aged ≥75 years. Patients ≥75 years had significantly more pharmacologically active substances prescribed than patients aged ≤54 years (mean 5.8 vs 3.8, respectively; p < 0.001). Cardiovascular diseases such as coronary heart disease, heart failure or arrhythmias were also significantly more prevalent in patients aged ≥75 years than in younger patients. The overall prevalence of pDDIs increased significantly from 7.9% in those aged ≤54 years to 18.4% in patients aged ≥75 years (p < 0.001). The frequency of both pDDIs associated with statins and non-statin pDDIs increased with age. Risk factors for pDDIs in patients aged ≥75 years were arrhythmias, heart failure and the number of pharmacologically active substances prescribed. The more frequent prescription of cardiovascular drugs with a high potential for pDDIs (e.g. amiodarone and digoxin) in patients aged ≥75 years was mainly responsible for the observed increases in statin and non-statin pDDIs in this age group.


Compared with younger patients, elderly dyslipidaemic patients are at a higher risk for clinically relevant pDDIs, mainly because of a higher number of drugs prescribed. In addition, patients aged ≥75 years were prescribed more drugs with a high potential for DDIs, especially drugs used for the treatment of arrhythmias and heart failure. The risk for adverse reactions associated with pDDIs may often be reduced by dose adjustment, close monitoring or selection of an alternative drug.


Statin Digoxin Simvastatin Atorvastatin Amiodarone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was financially supported by Bristol-Myers Squibb, GmbH, Baar, Switzerland. The sponsors had no influence on the study design, analysis and interpretation of data or writing of the manuscript.

Stephan Krähenbühl is supported by a grant from the Swiss National Science Foundation (310’000-112483/1). Stephan Krähenbühl and Lorenzo Hess have received grants from Bristol-Myers Squibb, GmbH, Baar, Switzerland. Raymond Schlienger is employed by Novartis Pharma, Switzerland. None of the authors has any conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 1996 Aug; 44(8): 944–8PubMedGoogle Scholar
  2. 2.
    Kohler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000 Nov; 38(11): 504–13PubMedGoogle Scholar
  3. 3.
    Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf 2006; 29(1): 79–90PubMedCrossRefGoogle Scholar
  4. 4.
    Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003 Mar; 58(11): 773–8PubMedGoogle Scholar
  5. 5.
    Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28(1): 67–80PubMedCrossRefGoogle Scholar
  6. 6.
    Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001 Dec; 15(6): 897–918PubMedCrossRefGoogle Scholar
  7. 7.
    Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993 Jul; 9(1): 51–9PubMedCrossRefGoogle Scholar
  8. 8.
    Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76PubMedCrossRefGoogle Scholar
  9. 9.
    Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998 Jun; 12(6): 485–94PubMedCrossRefGoogle Scholar
  10. 10.
    Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003 Sep; 21(3): 153–8PubMedCrossRefGoogle Scholar
  11. 11.
    Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28(3): 263–75PubMedCrossRefGoogle Scholar
  12. 12.
    Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, et al. Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy. Schweiz Rundsch Med Prax 2006 Feb 1; 95(5): 139–46Google Scholar
  13. 13.
    WHO drug dictionary. Version 01–3, third quarter. Uppsala: WHO Collaborating Centre, 2001Google Scholar
  14. 14.
    Thomson Micromedex. DRUG-REAX® System [online]. Available from URL: [Accessed 2002 Apr 30]
  15. 15.
    ICH Topic E2A. Clinical safety data management: definitions and standards for expedited reporting. London: The European Agency for the Evaluation of Medicinal Products, 1994Google Scholar
  16. 16.
    Stockley IH, editor. Drug interactions. London: The Pharmaceutical Press, 1999Google Scholar
  17. 17.
    Tatro DS, editor. Drug interaction facts™. Updated 2003 Jan. St Louis (MO): Facts and Comparisons, 2003Google Scholar
  18. 18.
    e-mediat. Pharmavista databases: interactions [online]. Available from URL: [Accessed 2002 Apr 30]
  19. 19.
    Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65–70Google Scholar
  20. 20.
    Sauro J, Lewis JR. Estimating completion rates from small samples using binomial confidence intervals: comparisons and recommendations. In: Proceedings of the Human Factors and Ergonomics society: 49th Annual Meeting; 2005 Sep 26–30; Orlando (FL). Santa Monica (CA): Human Factors and Ergonomics Society, 2005: 2100–4Google Scholar
  21. 21.
    Roten L, Schoenenberger RA, Krähenbühl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004 Jun; 38(6): 978–81PubMedCrossRefGoogle Scholar
  22. 22.
    Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41(5): 343–70PubMedCrossRefGoogle Scholar
  23. 23.
    Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Stroke 2002 Sep; 33(9): 2337–41PubMedCrossRefGoogle Scholar
  24. 24.
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97Google Scholar
  25. 25.
    Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I. Aging arteries: a “set up” for vascular disease. Circulation 2003 Jan 7; 107(1): 139–46PubMedCrossRefGoogle Scholar
  26. 26.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2; 341(10): 709–17PubMedCrossRefGoogle Scholar
  27. 27.
    Shah KB, Rao K, Sawyer R, et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005 Sep 6; 46(5): 845–9PubMedCrossRefGoogle Scholar
  28. 28.
    Wrenger E, Müller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003 Jul 19; 327(7407): 147–9PubMedCrossRefGoogle Scholar
  29. 29.
    Gheorghiade M, Adams Jr KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004 Jun 22; 109(24): 2959–64PubMedCrossRefGoogle Scholar
  30. 30.
    Miura T, Kojima R, Sugiura Y, et al. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother 2000 Apr; 34(4): 427–32PubMedCrossRefGoogle Scholar
  31. 31.
    Marik PE, Fromm L. A case series of hospitalized patients with elevated digoxin levels. Am J Med 1998 Aug; 105(2): 110–5PubMedCrossRefGoogle Scholar
  32. 32.
    Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl 1981; 647: 75–8PubMedGoogle Scholar
  33. 33.
    Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998 Jul; 64(1): 123–8PubMedCrossRefGoogle Scholar
  34. 34.
    Bachmakov I, Werner U, Endress B, et al. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 2006 Jun; 20(3): 273–82PubMedCrossRefGoogle Scholar
  35. 35.
    Wermeling DP, Field CJ, Smith DA, et al. Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy 1994 Sep–Oct; 14(5): 600–6PubMedGoogle Scholar
  36. 36.
    De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990 Apr; 29(4): 486–90PubMedCrossRefGoogle Scholar
  37. 37.
    Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006 Mar; 23(3): 506–12PubMedCrossRefGoogle Scholar
  38. 38.
    Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993 Sep; 36(3): 263–5PubMedCrossRefGoogle Scholar
  39. 39.
    Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994 Jun 6; 96(6A): 84S–6SPubMedCrossRefGoogle Scholar
  40. 40.
    Lemma GL, Wang Z, Hamman MA, et al. The effect of short-and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006 Mar; 79(3): 218–30PubMedCrossRefGoogle Scholar
  41. 41.
    Sutton D, Butler AM, Nadin L, et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997 Jul; 282(1): 294–300PubMedGoogle Scholar
  42. 42.
    Ohyama K, Nakajima M, Suzuki M, et al. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000 Mar; 49(3): 244–53PubMedCrossRefGoogle Scholar
  43. 43.
    Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004 Jun 15; 109 (23 Suppl. 1): III50–7PubMedCrossRefGoogle Scholar
  44. 44.
    Martin J, Krum H. Cytochrome P450 drag interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26(1): 13–21PubMedCrossRefGoogle Scholar
  45. 45.
    Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000 Jun; 22(6): 441–57PubMedCrossRefGoogle Scholar
  46. 46.
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006 Apr 17; 97(8A): 52C–60CPubMedCrossRefGoogle Scholar
  47. 47.
    Snowdon J. Is depression more prevalent in old age? Aust N Z J Psychiatry 2001 Dec; 35(6): 782–7PubMedCrossRefGoogle Scholar
  48. 48.
    Stewart DE. Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003; 64Suppl. 7: 12–6PubMedGoogle Scholar
  49. 49.
    Nelson JC. Diagnosing and treating depression in the elderly. J Clin Psychiatry 2001; 62Suppl. 24: 18–22PubMedGoogle Scholar
  50. 50.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8–22; 163(22): 2716–24PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Sabin S. Egger
    • 1
  • Alexandra E. Rätz Bravo
    • 1
  • Lorenzo Hess
    • 2
  • Raymond G. Schlienger
    • 1
  • Stephan Krähenbühl
    • 1
  1. 1.Clinical Pharmacology & ToxicologyUniversity Hospital BaselBaselSwitzerland
  2. 2.Brunner & Hess Software AGZürichSwitzerland

Personalised recommendations